Skip to main content

Eton Pharmaceuticals Inc

For the period ended Dec 31, 2023. Filed Mar 14, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 14, 2024

ETON$64.35+14.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned thereunto duly authorized.

ETON PHARMACEUTICALS, INC.
March 14, 2024By:/s/ Sean E. Brynjelsen
Sean E. Brynjelsen
President and Chief Executive Officer
(Principal Executive Officer)
By:/s/ James Gruber
James Gruber
Chief Financial Officer
(Principal Financial and Accounting Officer)

POWER OF ATTORNEY

Each person whose signature appears below constitutes and appoints each of Sean Brynjelsen and James Gruber, his or her true and lawful attorney-in-fact and agent, each with full power of substitution and resubstitution, severally, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K of Eton Pharmaceuticals, Inc., and any or all amendments thereto, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney may be executed in counterparts.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned thereunto duly authorized.

SignatureTitleDate
/s/ Sean E. BrynjelsenPresident, Chief Executive Officer, and DirectorMarch 14, 2024
Sean E. Brynjelsen(Principal Executive Officer)
/s/ James GruberChief Financial Officer, Treasurer and SecretaryMarch 14, 2024
James Gruber(Principal Financial and Accounting Officer)
/s/ Jennifer M. AdamsDirectorMarch 14, 2024
Jennifer M. Adams
/s/ Charles J. CasamentoDirectorMarch 14, 2024
Charles J. Casamento
/s/ Paul V. MaierDirectorMarch 14, 2024
Paul V. Maier
/s/ Norbert G. Riedel, Ph.D.DirectorMarch 14, 2024
Norbert G. Riedel, Ph.D.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.